ストックスクリーナーアプリを入手
2.07
1.90%
-0.04
前日終値:
$2.11
開ける：
$2.11
24時間の取引高:
101.48K
Relative Volume:
0.42
時価総額：
$153.66M
収益：
-
当期純損益:
$-2.95M
株価収益率:
-51.49
EPS:
-0.0402
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-4.61%
1か月 パフォーマンス:
-15.51%
6か月 パフォーマンス:
-94.94%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$1.9999
$2.11
1週間の範囲:
$1.9999
$2.31
52週間の値動き範囲:
$1.43
$67.00
Jyong Biotech Ltd Stock (MENS) Company Profile
Compare MENS vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MENS
Jyong Biotech Ltd
|
2.07 | 156.63M | 0 | -2.95M | 0 | -0.0402 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Jyong Biotech Ltd (MENS) 最新ニュース
Jyong Biotech Delays Annual 20-F (Yearly Report) - The Globe and Mail
Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio - Yahoo Finance
Two plant-based prostate drug candidates move toward broader markets - Stock Titan
Short Interest in Jyong Biotech Ltd. (NASDAQ:MENS) Decreases By 43.2% - MarketBeat
CEO-linked entities report 33.34% Jyong Biotech (MENS) stake via trust - Stock Titan
Jyong Biotech (MENS) Management Strategy | Q1 2025: Earnings ReportPre Earnings - Cổng thông tin điện tử tỉnh Lào Cai
MENS Stock Price, Quote & Chart | JYONG BIOTECH LTD (NASDAQ:MENS) - ChartMill
Who Backs Jyong Biotech (MENS) Stock (Risk Aversion) 2026-04-20Investment Picks - Cổng thông tin điện tử tỉnh Tây Ninh
Ming Tsan Hsu Net Worth (2026) - GuruFocus
Pang Chieh Chi Net Worth (2026) - GuruFocus
Feng Lin Hsu Net Worth (2026) - GuruFocus
Fu Feng Kuo Net Worth (2026) - GuruFocus
Jyong Biotech Ltd. (NASDAQ:MENS) Sees Significant Decrease in Short Interest - MarketBeat
Jyong Biotech Ltd. Live Share Prices and Trades. MENS.US Live Streaming Share Prices. - London South East
Jyong Biotech (NASDAQ: MENS) CFO ZHANG WEI files initial Form 3 - Stock Titan
Wei (vivi) Zhang Net Worth (2026) - GuruFocus
MENS Options Volatility — NASDAQ:MENS - TradingView
MENS Options Chain — NASDAQ:MENS - TradingView
MENS News | JYONG BIOTECH LTD (NASDAQ:MENS) - ChartMill
Jyong Biotech (MENS) CEO Kuo reports 25,349,500-share indirect stake on Form 3 - Stock Titan
Is Jyong Biotech (MENS) Stock Rebounding | Price at $2.47, Up 0.82%Real Trader Network - Newser
MENS PE Ratio & Valuation, Is MENS Overvalued - Intellectia AI
Director of Jyong Biotech (MENS) files Form 3 showing 3,000 common shares - Stock Titan
Director Hsu Feng-Lin reports 3,000 Jyong Biotech (MENS) shares on Form 3 - Stock Titan
Director at Jyong Biotech (MENS) discloses holding 3,000 shares - Stock Titan
Jyong Biotech (MENS) director Fan Hung-Shu files initial Form 3 - Stock Titan
Jyong Biotech (MENS) director files Form 3 with no insider trades - Stock Titan
Jyong Biotech Ltd. (NASDAQ:MENS) Short Interest Down 22.7% in March - Defense World
Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2 - The Manila Times
Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS-2 - Bitget
Jyong Biotech Ltd PE Ratio (TTM) & PE Ratio (TTM) ChartsMENS - GuruFocus
Chinese firm sues Taiwan’s Jyong Biotech Ltd. in Cayman to enforce ¥152M China judgment - OffshoreAlert
Jyong Biotech Ltd. (NASDAQ:MENS) Sees Large Decrease in Short Interest - MarketBeat
Jyong Biotech 'not aware' of any material information amid share price movement - MSN
MENS Earnings History & Surprises | EPS & Revenue Results | JYONG BIOTECH LTD (NASDAQ:MENS) - ChartMill
MENS Should I Buy - Intellectia AI
Jyong Biotech (NASDAQ:MENS) Stock Price Down 12.3%Time to Sell? - MarketBeat
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Jyong Biotech Strengthens Preventive Medicine Position With Positive Phase II Data And Asian Expansion - BioPharma APAC
Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia - The Manila Times
MENS Technical Analysis & Stock Price Forecast - Intellectia AI
Prostate cancer therapy also lowers cholesterol in 2-year trial - Stock Titan
CEO Fu-Feng Kuo, Jyong Biotech Ltd.'s (NASDAQ:MENS) largest shareholder sees value of holdings go down 23% after recent drop - Yahoo Finance
Jyong Biotech appoints Wei (Vivi) Zhang as chief financial officer By Investing.com - Investing.com India
Jyong Biotech appoints Wei (Vivi) Zhang as chief financial officer - Investing.com Nigeria
Jyong Biotech Appoints Veteran Capital Markets Executive Wei Zhang as Chief Financial Officer - TipRanks
Jyong Biotech Ltd. (NASDAQ:MENS) Short Interest Update - MarketBeat
Jyong Biotech subsidiary announces phase II data for MCS-8 - TipRanks
Jyong Biotech Ltd (MENS) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):